Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Neoplasms 7Colorectal Neoplasms 5Digestive System Neoplasms 4Pancreatic Neoplasms 3Neoplasms, Glandular and Epithelial 3Neoplasms by Site 3Digestive System Diseases 3Pancreatic Diseases 2Neoplasms by Histologic Type 2Endocrine Gland Neoplasms 2Carcinoma, Pancreatic Ductal 2Carcinoma, Hepatocellular 2Adenocarcinoma 2Thymus Neoplasms 1Stomach Neoplasms 1Rectal Diseases 1Pancreatic cancer, adult 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Intestinal Neoplasms 1Intestinal Diseases 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1

Interventions

padeliporfin 4Nivolumab 4Gemcitabine 4Cyclophosphamide 4130-nm albumin-bound paclitaxel 4napabucasin 3Pemetrexed 3Fluorouracil 3Albumin-Bound Paclitaxel 3ficlatuzumab 2Trastuzumab 2Trabectedin 2Paclitaxel 2Leucovorin 2Irinotecan 2Bevacizumab 2sotorasib 1selinexor 1ribociclib 1relatlimab 1pralsetinib 1pembrolizumab 1pamiparib 1osimertinib 1nintedanib 1ipatasertib 1guadecitabine 1glutathione pegylated liposomal doxorubicin 1exemestane 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Neoplasms by Site × napabucasin × Clear all
NCT02753127 2023-11-15

CanStem303C

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,253 enrolled 18 charts
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Colorectal Neoplasms

NCT02993731 2023-11-15

CanStem111P

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,134 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡